Melatonin is an endogenous indoleamine with well known antioxidant
properties demonstrated in vitro, in animal and in human studies.
Therefore, melatonin is an attractive agent in the treatment of oxidative stress related diseases of the newborn. In newborn
humans, melatonin has been used at doses ranging from 0.1 to 100
mg/Kg; however, due to the lack of pharmacokinetic data in neonates,
it is difficult to establish a therapeutic effective dose.
|